Literature DB >> 27230040

The astrocytic response to the dopaminergic denervation of the striatum.

Ingrid Morales1,2, Alberto Sanchez1, Clara Rodriguez-Sabate2, Manuel Rodriguez3,4.   

Abstract

Increasing evidence suggests that the dopaminergic degeneration which characterizes Parkinson's disease starts in the striatal dopamine terminals and progresses retrogradely to the body of dopamine cells in the substantia nigra. The role of striatal astrocytes in the striatal initiation of the dopaminergic degeneration is little known. This work was aimed at studying the astrocytic response to the dopaminergic denervation of the striatum. The injection of 6-hydroxydopamine (25 μg) in the lateral ventricle of adult Sprague-Dawley rats induced a fast (4 h) and selective (unaccompanied by unspecific lesions of striatal tissue or microgliosis) degeneration of the dopaminergic innervation of the striatum which was followed by a selective astrocytosis unaccompanied by microgliosis. This astrocytosis was severe and had a specific profile which included some (e.g. up-regulation of glial fibrillary acidic protein, GS, S100β, NDRG2, vimentin) but not all (e.g. astrocytic proliferation or differentiation from NG2 cells, astrocytic scars, microgliosis) the characteristics observed after the non-selective lesion of the striatum. This astrocytosis is similar to those observed in the parkinsonian striatum and, because it is was unaccompanied by changes in other striatal cells (e.g. by microgliosis), it may be suitable to study the role of striatal astrocytes during the dopaminergic denervation which characterizes the first stages of Parkinson's disease. The dopaminergic denervation of the striatum induced a severe astrogliosis with a specific profile which included some (e.g. up-regulation of GFAP, GS, S100β, NDRG2, vimentin) but not all (e.g. astrocytic proliferation or differentiation from NG2 cells, astrocytic scars, microgliosis) the characteristics observed after the non-selective striatal lesions. This response may help to understand the role of striatal astrocytes during the dopaminergic denervation which characterizes the first stages of PD. Cover Image for this issue: doi: 10.1111/jnc.13336.
© 2016 International Society for Neurochemistry.

Entities:  

Keywords:  6OHDA; Parkinson's disease; astrocyte; dying-back degeneration; lateral ventricle; microglia; striatum

Mesh:

Substances:

Year:  2016        PMID: 27230040     DOI: 10.1111/jnc.13684

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  10 in total

1.  Morphological Changes in a Severe Model of Parkinson's Disease and Its Suitability to Test the Therapeutic Effects of Microencapsulated Neurotrophic Factors.

Authors:  C Requejo; J A Ruiz-Ortega; H Bengoetxea; A García-Blanco; E Herrán; A Aristieta; M Igartua; J L Pedraz; L Ugedo; R M Hernández; J V Lafuente
Journal:  Mol Neurobiol       Date:  2016-11-14       Impact factor: 5.590

2.  Trafficking of the glutamate transporter is impaired in LRRK2-related Parkinson's disease.

Authors:  Ludovica Iovino; Veronica Giusti; Francesca Pischedda; Elena Giusto; Nicoletta Plotegher; Antonella Marte; Ilaria Battisti; Angela Di Iacovo; Algerta Marku; Giovanni Piccoli; Rina Bandopadhyay; Carla Perego; Tiziana Bonifacino; Giambattista Bonanno; Cristina Roseti; Elena Bossi; Giorgio Arrigoni; Luigi Bubacco; Elisa Greggio; Sabine Hilfiker; Laura Civiero
Journal:  Acta Neuropathol       Date:  2022-05-21       Impact factor: 15.887

Review 3.  Function and therapeutic value of astrocytes in neurological diseases.

Authors:  Hong-Gyun Lee; Michael A Wheeler; Francisco J Quintana
Journal:  Nat Rev Drug Discov       Date:  2022-02-16       Impact factor: 112.288

Review 4.  Emerging role of S100B protein implication in Parkinson's disease pathogenesis.

Authors:  Efthalia Angelopoulou; Yam Nath Paudel; Christina Piperi
Journal:  Cell Mol Life Sci       Date:  2020-10-14       Impact factor: 9.261

5.  Deleterious Effects of VEGFR2 and RET Inhibition in a Preclinical Model of Parkinson's Disease.

Authors:  C Requejo; J A Ruiz-Ortega; H Bengoetxea; S Bulnes; L Ugedo; J V Lafuente
Journal:  Mol Neurobiol       Date:  2018-01       Impact factor: 5.590

Review 6.  Neuron-Astrocyte Interactions in Parkinson's Disease.

Authors:  Ikuko Miyazaki; Masato Asanuma
Journal:  Cells       Date:  2020-12-07       Impact factor: 6.600

7.  Unilateral Intrastriatal 6-Hydroxydopamine Lesion in Mice: A Closer Look into Non-Motor Phenotype and Glial Response.

Authors:  Bárbara Mendes-Pinheiro; Carina Soares-Cunha; Ana Marote; Eduardo Loureiro-Campos; Jonas Campos; Sandra Barata-Antunes; Daniela Monteiro-Fernandes; Diogo Santos; Sara Duarte-Silva; Luísa Pinto; António José Salgado
Journal:  Int J Mol Sci       Date:  2021-10-26       Impact factor: 5.923

8.  Striatal astrocytes engulf dopaminergic debris in Parkinson's disease: A study in an animal model.

Authors:  Ingrid Morales; Alberto Sanchez; Clara Rodriguez-Sabate; Manuel Rodriguez
Journal:  PLoS One       Date:  2017-10-13       Impact factor: 3.240

9.  Connexin 30 deficiency attenuates A2 astrocyte responses and induces severe neurodegeneration in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride Parkinson's disease animal model.

Authors:  Atsushi Fujita; Hiroo Yamaguchi; Ryo Yamasaki; Yiwen Cui; Yuta Matsuoka; Ken-Ichi Yamada; Jun-Ichi Kira
Journal:  J Neuroinflammation       Date:  2018-08-13       Impact factor: 8.322

10.  Astrocytes and retrograde degeneration of nigrostriatal dopaminergic neurons in Parkinson's disease: removing axonal debris.

Authors:  Ingrid Morales; Ricardo Puertas-Avendaño; Alberto Sanchez; Adrian Perez-Barreto; Clara Rodriguez-Sabate; Manuel Rodriguez
Journal:  Transl Neurodegener       Date:  2021-11-02       Impact factor: 8.014

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.